Safely Returning to Clinical Trials


Since the coronavirus pandemic started, clinical trial recruitment and enrollment is down 40-60% across therapeutic areas. As the quarantine period ends, we are left with many questions about how to safely move forward with research, especially for patients suffering from serious, life-threatening diseases that might increase their risk of dying from COVID-19. This session will bring together the experts who sponsor, conduct, staff, and recruit clinical trials to discuss the challenges and potential solutions that will enable continued access to novel, life-saving medications for patients around the world.


Catherine Owen
Senior Vice President, Major Markets, Bristol Myers Squibb
View Bio
Kathleen Griffin
Executive Director, Partnerships and Digital Engagement, Syneos Health
View Bio
Dr. Amy C. Moore
Director, Science & Research, GO2 Foundation for Lung Cancer
View Bio
Upal Basu Roy PhD, MPH
Vice President of Research, LUNGevity Foundation
View Bio
Christopher D. Ferris MD, PhD, MPH
Gastroenterologist, Tryon Medical Partners
View Bio
Dave Craig
CEO and CoFounder, GRYT Health
View Bio